GEN Exclusives

More »

Feature Articles

More »
Jun 15, 2013 (Vol. 33, No. 12)

Exploring Exosomal RNA

  • Biomarker Potential

    The University of Notre Dame’s Jeffrey Schorey, Ph.D., seeks to harness the power of exosomal RNA as a biomarker for Mycobacterium tuberculosis-infected macrophages. Speaking at the ISEV meeting, Dr. Schorey, professor and associate director, Institute for Global Health, Center for Rare and Neglected Diseases, emphasized the potential advantages of exosomes in tuberculosis (TB) diagnostics—namely, easy isolation from various bodily fluids, potential enrichment of TB components present in bodily fluids, and potential detection of TB RNA, TB proteins, and other TB components from a single source.

    “For the sequencing of our cDNA library, which was made from the small RNA isolated from exosomes, we used the Roche 454 Genome Sequencer FLX+ instrument,” Dr. Schorey explained. “Our goal was to define not only the microRNAs present in the exosomes, but other small RNA species. One of the surprising findings from our sequencing results is that the exosomes contained M. tuberculosis RNA.”

    From there, “we confirmed that the sequenced RNA was fragments of intact full-length transcripts as determined by RT-PCR of RNA isolated from exosomes released from infected macrophages,” he added.

    To date, Dr. Schorey and his colleagues have shown that exosomes produced by M. tuberculosis-infected macrophages have a unique repertoire of miRNAs and mRNAs, and that these microvesicles carry mycobacterial proteins and mRNA transcripts and have immune modulatory activity.

    Over at the VU University Medical Center in Amsterdam, immunology Michiel Pegtel, Ph.D. and his colleagues are examining how nonrandom small RNA identified in tumor exosomes show biomarker potential. They are taking a deep sequencing approach for these studies.

    “In contrast to closed profiling technologies such as microarray and RT-PCR arrays, deep sequencing has literally opened our eyes on the complexity of the human transcriptome. Our previous work using individual quantitative RT-PCR could demonstrate that human B cells infected with the tumor virus Epstein Barr (EBV) secrete exosomes that contain fully mature and functional virus-encoded miRNAs,” Dr. Pegtel noted.

    “At the ISEV meeting, Nobel laureate Dr. Phillip Sharp stressed the importance of quantitation in RNA research. I could not agree more as this applies directly to research concerning transfer of functional RNA via exosomes.”

    Dr. Pegtel explained that in his team’s virus model, scientists could show that the transfer of relatively small copy numbers of miRNAs from an EBV-infected B cell into an uninfected recipient dendritic cell could directly influence gene regulation.

    “Quantitation of RNA copy numbers in exosomes is important, but perhaps it is less important how many are in one or a thousand exosomes,” he said. “More important is what is actually transferred from one cell to another.”

    He and his colleagues are now using the Illumina HiSeq 2000 and 100 paired-end protocol on both cancer cells and secreted exomes. Working in collaboration with the University of Granada’s Michael Hackenberg, Ph.D., assistant professor, Dr. Pegtel et al., have found that, aside from the presence of nearly all small RNA families, many smaller RNA fragments are preferentially sorted or excluded from secretion by exosomes indicating an underlying biology.

    “Perhaps more interesting is that these small RNA fragments do not adhere to the general rules for Dicer-dependent miRNA processing,” Dr. Pegtel added. “Thus, deep sequencing has revolutionized not only what we know about RNAs inside cells, but also what is secreted into the extracellular milieu that can be used for diagnostics. Because of the quantitative nature of deep sequencing technology, we have gained additional insights into the potential mechanisms that control secretion of known and newly discovered RNAs via exosomes.”

    He said that further research in this area will eventually tell scientists more about cell-cell communication in both health and disease. “Decoding the messages that are sent out by, for instance, cancerous cells will hopefully improve and simplify diagnosis such that we will all benefit from this exciting work,” Dr. Pegtel said.


Readers' Comments

Posted 01/31/2014 by Mark

WOW...OK, I do not know if these papers are the result of fraud or misconduct as you suggest but I guess that it is good that people know that the method does not work so they do not burn their money, tough situation though.

Posted 10/23/2013 by anonymous

Thank you, the content and the work cited in this article is excellent. Clearly exosome biology is very important and maybe one day treatments will go into the clinic. It is a pity that the field has lost some credibility because all the fuss in the media about the use of exosomes to deliver siRNAs across the blood brain barrier that finished in fiasco. I mean has anybody being able to replicate the results Alvarez-Erviti 2011 or El Andaloussi 2012? Both works are from the same people and I know several top groups that have tried to replicate their results unsuccessfully. This is like the RVG siRNA of Kumar 2007, I cannot believe that Nature does not retract these papers and make so many people lose their time. I guess that they also make money from the advertisements and do not care that citations come from reviews and discussions rather than from other groups replicating their results and using exosomes to deliver siRNAs across the blood brain barrier or in other case what are they waiting for?

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?